Live Feeds
● LIVE Updated 1h ago · 8 sources tracked

Argenx to acquire Unnatural Products in deal worth up to $1.15B

Biopharmaceutical company Argenx has agreed to acquire Unnatural Products in a transaction valued at up to $1.15 billion. The buyout gives Argenx control of an artificial intelligence-guided macrocycle discovery platform. By integrating this platform with its own antibody engineering expertise, Argenx aims to expand its capabilities in oral peptides and next-generation immunology medicines. The deal positions the company to develop macrocyclic peptide drugs that can target complex biological pathways previously difficult to reach with traditional biologics.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Argenx is acquiring Unnatural Products in a deal worth up to $1.15 billion.
  • ✓ The transaction adds an artificial intelligence-guided macrocyclic peptide discovery platform to Argenx.
  • ✓ The acquisition expands Argenx capabilities in oral peptides and immunology.
🛡️ Source Corroboration: 8 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Argenx has officially agreed to purchase Unnatural Products in a deal worth up to $1.15 billion to expand into oral peptides.

Live updates

  1. Argenx Agrees to Buy Unnatural Products for $1.15 Billion

    Biopharmaceutical company Argenx has agreed to acquire Unnatural Products in a transaction valued at up to $1.15 billion. The buyout gives Argenx control of an artificial intelligence-guided macrocycle discovery platform. By integrating this platform with its own antibody engineering expertise, Argenx aims to expand its capabilities in oral peptides and next-generation immunology medicines. The deal positions the company to develop macrocyclic peptide drugs that can target complex biological pathways previously difficult to reach with traditional biologics.

    Why it matters

    The acquisition represents a strategic push by Argenx to broaden its therapeutic reach beyond conventional antibody treatments. Unnatural Products brings specialized technology designed to solve longstanding challenges in medicinal chemistry by turning difficult biological targets into druggable opportunities. This buyout highlights a broader industry trend of large biopharmaceutical companies investing heavily in artificial intelligence-driven discovery engines.

    What is confirmed

    • Argenx is acquiring Unnatural Products in a deal worth up to $1.15 billion.
    • The transaction adds an artificial intelligence-guided macrocyclic peptide discovery platform to Argenx.
    • The acquisition expands Argenx capabilities in oral peptides and immunology.

    What to watch next

    • Closing of the acquisition transaction
    • Integration updates regarding the macrocycle discovery platform and antibody engineering
    Sources used for this update (8)
    1. www.fiercebiotech.com — Fierce Biotech News & Reports
    2. Endpoints News — Argenx to acquire Unnatural Products in deal worth up to $1.15B
    3. Fierce Biotech — Argenx inks $1.15B Unnatural Products buyout to expand in oral peptides
    4. PharmTech.com — $1.15B AI-Guided Macrocycle Discovery Lands at argenx
    5. Bloomberg.com — Argenx to Buy US Biotech for $1.15 Billion to Gain Peptides
    6. GlobeNewswire — Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
    7. FirstWord Pharma — argenx to buy Unnatural Products for up to $1.15B
    8. www.pharmexec.com — argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community